Merck asks DC federal court for IRA decision 'as soon as practicable'
Merck was the first pharmaceutical company to file suit against the Inflation Reduction Act in June 2023. But more than a year later, it still doesn’t have a decision. On Wednesday, the company asked...
View ArticleClik here to view.
Exclusive: TMRW Life Sciences raises $28M Series D to upgrade storage for egg...
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) TMRW Life Sciences has raised more money for its technology for freezing, tracking and monitoring eggs...
View ArticleClik here to view.
FDA blocks Agenus' accelerated approval plans for CTLA-4/PD-1 combo
Agenus is shelving immediate plans for a confirmatory Phase 3 study for its lead immunotherapy program after the FDA “discouraged” it from filing for accelerated approval and asked for a “definitive...
View ArticleNovartis on 'streamlining' development, MorphoSys drug and radioligand...
More than two years after Novartis first announced a global restructuring that affected 8,000 positions, the pharma giant says its workforce has settled into the simplified structure befitting its...
View ArticleClik here to view.
KRAS cancer drug eased symptoms of rare and serious blood vessel condition in...
The advent of new targeted oncology therapies may benefit more than just cancer patients. Two patients with severe arteriovenous malformations — an ultra-rare condition where a group of blood vessels...
View ArticleClik here to view.
#ASRS24: Roche touts Phase 3 Susvimo data in diabetes-related ophthalmic...
Roche has unveiled new two-year data from late-stage studies of its ocular implant Susvimo in patients with diabetic eye conditions, as the Swiss pharma works to relaunch the product in a separate...
View ArticleClik here to view.
GoodRx launches discount for Boehringer Ingelheim's Humira biosimilar
Boehringer Ingelheim has partnered with GoodRx to offer the drugmaker’s Humira biosimilar, adalimumab-adbm, in another move by manufacturers to try and wedge themselves into a market still dominated by...
View ArticleClik here to view.
Phathom wins label expansion on heartburn drug to include non-erosive patients
Phathom Pharmaceuticals is digesting news of an expanded label for its heartburn drug Voquezna. The FDA on Wednesday afternoon approved the drug for the relief of heartburn associated with non-erosive...
View ArticleSanofi seeks deeper roots in India with €400M hub expansion
India is soon to become host to Sanofi’s largest global capacity center as the French pharma plans to spend €400 million ($437 million) and more than double its workforce in Hyderabad. The company is...
View ArticleJ&J ditches epilepsy collaboration with Addex, blindsiding 20-year...
Geneva-based Addex Therapeutics has lost its 20-year relationship with Johnson & Johnson a few months after their partnered epilepsy drug flunked a mid-stage test. A J&J spokesperson told...
View ArticleParker Institute for Cancer Immunotherapy invests another $125M into research
The Parker Institute for Cancer Immunotherapy, a research network established by tech entrepreneur Sean Parker, announced a new $125 million investment. The latest investment comes from Parker and his...
View ArticleCatalent finishes German expansion; Grünenthal invests in Latin America
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Catalent completed its $25 million expansion at a facility in...
View ArticleBoehringer plans to again increase R&D spending; Valneva, Pfizer to advance...
Plus, news about OPKO, HealthCare Royalty, Inventiva, Exscientia and GT Apeiron: Boehringer Ingelheim ups its R&D budget: Back in April, the company said it would invest €36 billion ($39 billion)...
View ArticleNovartis CEO: Trying to crack obesity market with another first-gen agent is...
Novartis doesn’t want to play the me-too game in obesity. On Thursday, CEO Vas Narasimhan said that trying to compete in the multibillion-dollar obesity market with an injectable or oral GLP-1 or GIP...
View ArticleAveo Oncology’s Fotivda combo fails in Phase 3 kidney cancer test
Adding an immune checkpoint inhibitor did not improve the performance of Aveo Oncology’s Fotivda in a late-phase study in certain patients with renal cell carcinoma, nipping the company’s hopes for a...
View ArticleQ&A: How argenx’s CEO plans to create a sequel to Vyvgart (and beat the IRA)
Tim Van Hauwermeiren is one of Europe’s most successful biotech entrepreneurs, having turned a €1 million investment crisis into a drug company worth more than $28 billion today. The Dutch company’s...
View ArticleArdelyx sues Medicare over attempt to change coverage for dialysis drug
Ardelyx and two kidney patient advocacy groups are suing the US government over plans to change how certain drugs used by dialysis patients are paid for, shifting them out of Medicare’s Part D program...
View ArticleClik here to view.
Artiva's IPO raises $167M to fund company's autoimmune and cancer cell therapies
Cell therapy startup Artiva Biotherapeutics will go public on Friday morning in the 11th biotech IPO this year. Its Wall Street debut adds to the industry’s modest rebuilding in 2024 following a dismal...
View ArticleGRO Biosciences raises $60M for protein therapies from genomically recoded...
A biotech startup trying to expand the limited palette that nature uses to make proteins has raised funds to test its creations in humans for the first time. The company, called GRO Biosciences, is...
View ArticleClik here to view.
Nadir Mahmood returns to Nkarta a year after leaving; BeiGene picks longtime...
Nadir Mahmood For new Nkarta president Nadir Mahmood, home is where the heart is. The five-year veteran of the NK cell therapy biotech is returning after a brief stint as CEO at Rezo Therapeutics....
View Article